Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

$40 Million in Total Proceeds Retire Safeguard Mezzanine Debt Facility; Support Profitable Growth

ALISO VIEJO, Calif., May 18 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, announced today that it has completed the second tranche of a private placement of convertible preferred stock with Oak Investment Partners, a multi-stage venture capital firm based in Westport, CT. The second tranche for approximately $10.9 million, combined with $29.1 million in proceeds from the first tranche that closed March 26, 2009, will retire $31 million in Clarient borrowings and bolster working capital.

"As we stated in the initial financing announcement, this transaction strengthens Clarient's financials, streamlining our balance sheet and moving us tangibly closer to our goal of sustainable profitability," said Ron Andrews, Vice Chairman and Chief Executive Officer. "Oak is an excellent strategic partner with deep expertise in life sciences that will help Clarient continue its robust growth and expand our share of the dynamic cancer-diagnostic services market."

Clarient intends to retire a $10 million mezzanine debt facility from Safeguard Delaware, Inc., a wholly owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE), a provider of growth capital for entrepreneurial and innovative technology and life sciences companies based in Wa
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering.      ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 ... services MeMD, Inc proudly announces the release of ... Health and Fitness ". , MeMD's goal was ... ever-changing landscape of Health 2.0, Health 3.0 and ... will likely transform medical care and the fitness ...
(Date:6/18/2013)... WA (PRWEB) June 18, 2013 Though ... -- 11,000, according to the U.S. Bureau of Labor Statistics ... increase of 24,000 per month. Most new health care jobs ... the hospital sector saw a loss of 6,000 jobs. Overall, ... outplacement consultancy firm Challenger, Gray & Christmas reported that a ...
(Date:6/18/2013)... Minneapolis, MN (PRWEB) June 18, 2013 ... the Saniclave 200 prevent the dangers of ... confusing features, like knobs, analog pressure gauges, hot surfaces ... older autoclave, or a new, modern autoclave, Revolutionary Science ... use fresh water. Older autoclave designs will recycle ...
Breaking Biology Technology:Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3How to Autoclave: Why the User Friendliness of the Saniclave 200 is So Important Today 2
... a dorm refrigerator in one of Himadri B. Pakrasi,s labs, a ... of red, blue and green LEDS. This isn,t just any ... is colored by a strain of blue-green bacteria that bubble off ... part because of their unique genetic endowment but also in part ...
... 14, 2010 BIOSAFE, Inc. has announced that ... water-based antimicrobial solutions and entered into a commercialization ... products containing BIOSAFE,s patented and exclusive antimicrobial polymer, ... protects surfaces from harmful and degrading effects of ...
... 2010 Tolerx, Inc., a biopharmaceutical company developing novel ... T cell activity, today announced that it has initiated ... tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal ... T cells to more effectively attack cancer cells.   ...
Cached Biology Technology:Champion hydrogen-producing microbe 2Champion hydrogen-producing microbe 3Champion hydrogen-producing microbe 4Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals 2Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3
(Date:6/17/2013)... sugar alcohol produced by fungi, bacteria, and algae, is ... sweetener is also used in the medical field ... flush out excess fluids and used during surgery as ... the passage of other drugs. , Now Profs. Ehud ... of Molecular Microbiology and Biotechnology and the Sagol School ...
(Date:6/17/2013)... shale gas, is widespread across Pennsylvania, covering up to ... the Annals of the New York Academy of ... pollution from toxic chemicals, the building of well pads ... has engendered a great deal of controversy, largely because ... biological diversity and resources have scarcely been addressed in ...
(Date:6/16/2013)... a similar marine ecosystem crisis to those witnessed in ... to research published today in Nature Geoscience ., ... Newcastle, UK, Cologne, Frankfurt and GEOMAR-Kiel, confirms the link ... ecosystem during the mid-Cretaceous greenhouse period. It ... duration of the temperature change.,Analysing the geochemistry and micropaleontology ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2Global cooling as significant as global warming 2
... (fMRI) is a powerful noninvasive tool for studying brain ... studies are carried out on adults, but this technique ... That potential is hampered, however, by a lack of ... the developing brain. Now, by studying rats, MIT neuroscientists ...
... Technology recently received a research grant from the ... Functional Polymers Modified Surfaces with Biofilm Sensitizing Ability. ... Department of Chemistry and Chemical Biology, will serve ... is an assemblage of microbial cells that is ...
... called for the guidance documents for the implementation of ... The consensus among the scientists and stakeholders who discussed ... Environmental Research (UFZ) in November was that the Directive ... taken further. The experts can already see that the ...
Cached Biology News:Using fMRI to study brain development 2Further development of Water Framework Directive necessary 2Further development of Water Framework Directive necessary 3
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Biology Products: